1	
2	
3	
4	Coverage and factor associated to the uptake of Intermittent preventive treatment for
5	malaria during pregnancy (IPTp) in Cameroun in 2018: an analysis from the 2018
6	Cameroon Demographic Health Survey data
7	
ŗ	
8	
9	
10	Dominique Guimsop Ken ¹ , Ange Faustine Kenmogne Talla ¹ , Haoua Kodji ¹ , Jerome Ateudjieu ¹
11	
12	
13	¹ Departement of public health, Faculty of Medicine and Pharmaceutical Sciences, University
14	of Dschang, Dschang, Cameroon
15	
16	
17	* Corresponding author
18	E-mail: dk.guimsop@outlook.com

19 Abstract

Malaria in pregnancy is a major public health issue, contributing to significantly increasing mother and children mortality and morbidity. Intermittent preventive treatment of malaria using Sulfadoxine-Pyrimethamine (IPTp-SP) is one of the key interventions recommended by WHO and in Cameroon to reduce the morbidity of Malaria in Pregnancy. The present study aims to assess the distribution and determinants of poor uptake of IPTp-SP (< 3 doses) among pregnant women in Cameroon.

We conducted a secondary analysis of data extracted from the Cameroun Demographic Health Survey conducted in 2018. Data were collected using a questionnaire administered in face to face to mothers with at least one child under 5, selected using a 2-stage stratified sampling process. Frequencies of mothers exposed to less than 3 doses of IPTp-SP were estimated with a 95% CI. A case-control design was used to assess the association between key suspected determinants and being exposed to less than 3 doses of IPTp-SP. This was measured by estimating crude and adjusted Odd-Ratios (ORs).

33 A total of 13527 childbearing age women were interviewed, of which 5528 (40.9%) 34 met our selection criteria. Among those, 845 (15.3%) had not attended any Antenatal care 35 (ANC) visit, 1109 (20%) had attended 1 to 3 visits, 3379 (61.1%) had attended 4 to 7 visits and only 195 (3.5%) had attended at least 8 visits. In all, 3398 (61.5%, CI: 60.2-62.8) had received 36 37 less than 3 doses of IPTp-SP. Maternal age below 26 years (aOR=1.17, CI: 1.01-1.35), 38 residence in an area of lower malaria endemicity (aOR=1.26, CI: 1.00-1.58), residence in the 39 Sahelian regions (aOR=5.81, CI: 2.46-13.69), and having attended less than 4 ANC visits (aOR=1.30, CI: 1.08-1.57) were predictors of poor uptake of IPTp-SP. Conversely, residence 40 41 in major cities (aOR=0.65, CI: 0.50-0.84), having attended a first ANC visit at 3 months or less 42 of pregnancy (aOR=0.66, CI: 0.57-0.78) and having been followed on ANC by a medical doctor

43	(aOR=0.22, CI: 0.13-0.35), were preventing factors for poor uptake of IPTp3+. Highest level
44	of education (aOR= 1.10, CI: 0.90-1.32) was not found associated with the uptake of IPTp-SP.
45	Therefore, only a third of pregnant women in Cameroon take an optimal dose of IPTp-
46	SP. This proportion vary widely with the place of residence, being significantly low in the
47	Sahelian regions. Interventions to address identified determinants of low coverage of IPTp-SP
48	like maternal age below 26 years, ANC characteristics or being resident of area with lower
49	malaria endemicity ought to be tested.

- 50
- 51

52 Introduction

53 Malaria, caused in humans by five species of *Plasmodium*, remains one of the most 54 widespread infectious diseases. The heavy burden is mainly related to *Plasmodium falciparum* 55 and *Plasmodium vivax*. It threatens nearly half of the world's population, resulting in 229 56 million cases and 409.000 deaths in 2019, Africa accounting for over 90% of cases [1]. Malaria 57 is significantly known to increase the risk of maternal and fetal anemia, abortion, low birth 58 weight, and neonatal death [2-5]. To reduce the burden of the disease, efforts are channeled 59 into 3 main strategies: Intermittent Preventive Treatment in pregnancy with Sulfadoxine-60 Pyrimethamine (IPTp-SP), use of insecticide-treated nets, and effective case management in all 61 areas of moderate to severe transmission [6]. IPTp-SP policy recommends that each pregnant 62 woman receive at least three doses of Sulfadoxine-Pyrimethamine (SP) throughout her 63 pregnancy, each at least one month apart, which can be safely administered from 13 weeks to delivery [7, 8]. 64

Despite implemented interventions, the 3 doses IPTp-SP coverage in 2020 was 34%
 overall in the 33 countries that adopted the preventive measure [1]. The poor performance can

be explained by limited access to healthcare, poor training of health care providers, stock-outs
of the drugs, maternal and pregnancy-related factors as level of education and multigravidity
among others [9-12].

70 In Cameroon, the Ministry of Health adopted a new policy of chemoprevention of 71 malaria since May 2002 as part of ANC through the use of chloroquine, which was later 72 replaced in January 2004 by IPTp-SP following related WHO recommendations [13]. Available 73 literature estimated in 2018 the 3 doses coverage of IPTp-SP among pregnant women in 74 Cameroon between 23.5% and 54.9% depending on socio-demographic characteristics, 75 antenatal care performance, and study type [9, 14]. These figures lag clearly behind the 80% 76 coverage rate targeted by the country for 2023. No study has been conducted to understand 77 limitation of health care systems in achieving its objectives. While such finding would help 78 policymakers in their effort to improve the effectiveness of actual strategies or propose new 79 ones. The present study evaluated the distribution of poor uptake of ≥ 3 doses of IPTp-SP 80 among pregnant women in Cameroon and assessed its determinants.

81

82 Methodology

83 Study design and setting

We conducted a secondary data analysis of the 2018 Cameroon Demographic and Health Survey (DHS) [14]. The data were collected from a cross-sectional household-based survey targeting 22 territorial units of Cameroon including 10 regions (each parted into their respective urban and rural areas) and the two major cities of the country. One of the areas affected by the ongoing socio-political crisis was excluded. Household were selected by stratified cluster random sampling process and in each visited household the data were collected using a face-to-face administered questionnaire.

91

92

93 Study population

The target population was all women aged 15–49 years residing in the selected cluster and biological mother of a living child aged less than at the day the selected household is visited.

97

98 **Participants extraction from the data base**

From the variable "woman of childbearing age", we deducted the variable "mother of a under 5 years old child" by coding. From those selected we excluded participants who did not have recorded data on the age of the child, those who did not have data on whether or not they attented ANC visits and those did not have data on whether or not they took sulphadoxine pyrimethamine during the pregnancy of the child (Fig 1).

104 Fig 1. Flow diagram of sample selection from CDHS 2018 data.

105

106

107 Variable of interest

Data were extracted for analysis based on variables that were theoretically and empirically linked to the uptake of \geq 3 doses of IPTp-SP as follow: (a) the dependent variable was the number of women who had received less than three doses of IPTp-SP (Poor uptake of \geq 3 doses of IPTp-SP); (b) Independent variables comprised woman's age, stay in the place of residence, woman's highest educational level, religion, literacy, wealth, health insurance coverage, occupational status, matrimonial status, partner's highest level of education, region, area of residence, area's malaria prevalence, wanted pregnancy, parity, history of a terminated pregnancy, ANC highest attendant, number of ANC visits. Variables regarding pregnancy andprenatal care were relative to the most recent live birth.

117

118 Data management

Data extraction, grooming, and analysis were done using IBM SPSS Statistics version
26 (International business machines corp., New York, USA).

121 The complex sampling design of the survey was taken into account by using the 122 "Complex samples" functionality of IBM SPSS for the analyses, and except specified 123 otherwise, only weighted data were presented in our results.

124

125 Statistical analysis

126 Categorical variables were summarized as frequencies and proportions. In analytic 127 analysis, the Rao-Scott correction to Chi-square test was used to compare the distribution of 128 the independent variables between the two levels of our dependent variable. Bivariate logistic 129 regression was then used after all dependent variables were dichotomized, to measure the 130 association with our independent variable. Dependents that had an association with the outcome 131 significant at p<0.05 were selected for the multivariate logistic regression model. This 132 estimated adjusted odds ratio (aOR) and their significance, controlling for the effect of other 133 dependent variables. Collinearity was checked using Variance inflation factors (VIFs) 134 calculation. Finally, substantive cross-level interactions among our dependents were explored, and only one was found significant, which was kept in the model. The level of significance 135 136 used was 5% (0.05), two-tailed.

137

138 Ethical consideration

139	The Cameroon DHS protocol, including measuring procedures and biological tests, was
140	reviewed and approved by the Cameroonian ministry of health National ethical committee for
141	research and human health (CNERSH) and Inner-City Fund (ICF) Institutional Review Board.
142	Informed consent for the survey was obtained from each respondent before each interview.
143	Permission to access the Cameroonian DHS 2018 survey dataset for the present study was
144	obtained from the Demographic and Health Surveys (DHS) Program. Surveyors maintained
145	confidentiality by an anonymization technique attributing a code to every case. The accessed
146	data set was kept on a password-secured computer.
147	

148

149 **Results**

150 Characteristics of the population

We included 5528 participants from the database, with almost half (48.1%, n=2657) aged between 25 and 35 years old and 44.5% (n=2455) having attended at least secondary school. About half (52.6%, n=2911) of the women lived in rural areas, and they seem to be fairly distributed across wealth classes. Overall, 61.5% (n = 3398) of the study population had taken less than three doses of IPTp-SP (Table 1).

Table 1. Socio-demographic and environmental characteristics of participants and comparison between those who took less than 3 doses of IPTp-SP and others (N=5528)

Variables		IPTp-SP uptake, n (%)		Rao-Scott F(df1, df2)	р
	Total	<3 doses	3+ doses		
	N=5528	n=3398	n=2130		
Age groups (years)					
15-19	521 (9.4)	333 (9.8)	188 (8.8)	0.93 (4.53, 1846.71)	0.457
20-24	1205 (21.8)	760 (22.4)	445 (20.9)		
25-29	1496 (27.1)	918 (27.0)	578 (27.1)		
30-34	1161 (21.0)	703 (20.7)	459 (21.5)		

35-39	727 (13.1)	421 (12.4)	305 (14.3)		
40-49	416 (7.5)	262 (7.7)	155 (7.3)		
Stay in the place of residence					
Visitor	121 (2.2)	79 (2.2)	42 (2.0)	0.26 (2.83, 1158.50)	0.844
0-19 years	3454 (62.5)	2119 (62.4)	1334 (62.6)		
20-40] years	219 (4.0)	140 (4.1)	79 (3.7)		
Always	1734 (31.4)	1060 (31.2)	674 (31.7)		
Highest educational level					
No formal education	1425 (25.8)	996 (29.3)	429 (20.2)	16.24 (2.77, 1130.29)	< 0.001
Primary	1647 (29.8)	1058 (31.1)	590 (27.7)		
Secondary	2121 (38.4)	1185 (34.9)	936 (43.9)		
Higher	334 (6.1)	160 (4.7)	175 (8.2)		
Religion					
Animism/other	212 (3.8)	145 (4.3)	67 (3.1)	4.70 (1.97, 805.91)	0.010
Christian	3786 (68.5)	2246 (66.1)	1540 (72.3)		
Muslim	1530 (27.7)	1007 (29.6)	523 (24.6)		
Illiterate	2016 (36.5)	1391 (40.9)	625 (29.3)	30.88 (1.0, 408.0)	< 0.001
Combined wealth index					
Poorest	1111 (20.1)	779 (22.9)	331 (15.5)	22.38 (3.75, 1531.02)	< 0.001
Poorer	1215 (22)	842 (24.8)	374 (17.5)		
Middle	1135 (20.5)	734 (21.6)	401 (18.8)		
Richer	1100 (19.9)	587 (17.2)	514 (24.1)		
Richest	967 (17.5)	457 (13.5)	510 (23.9)		
Health insurance coverage	99 (1.8)	45 (1.3)	54 (2.5)	7.62 (1.0, 408.0)	0.006
Current occupation	3769 (68.3)	2306 (67.9)	1463 (68.7)	0.21 (1.0, 408.0)	0.650
Ever in union	4448 (80.5)	2767 (81.4)	1681 (78.9)	3.74 (1.0, 408.0)	0.054
Partner's highest level of education, secondary +	3636 (65.8)	2336 (68.8)	1299 (61)	21.87 (1.0, 408.0)	< 0.001
Region					
Sahelian regions	2025 (36.6)	1326 (39)	699 (32.8)	20.0 (1.94, 793.42)	< 0.001
Southern regions	2528 (45.7)	1611 (47.4)	917 (43.0)		
Douala/Yaounde	975 (17.6)	461 (13.6)	515 (24.2)		
Rural area of residence	2911 (52.6)	2000 (58.9)	911 (42.8)	48.75 (1, 41)	< 0.001
Area's malaria prevalence (%)					
0-9	1008 (18.2)	560 (16.5)	448 (21)	508.0 (2.82, 1150.09)	0.002
10-19	1717 (31.1)	1061 (31.2)	656 (30.8)		
20-29	1529 (27.7)	907 (26.7)	622 (29.2)		
30 +	1274 (23.1)	870 (25.6)	404 (19)		

158 IPTp-SP, Intermittent preventive treatment in pregnancy with Sulphadoxine pyrimethamine

159

Up to 845 (15.3 %) women did not attend any ANC visit. Among the 3574 (64.6 %) women 160 161 who attended the recommended number of visits, 1686 (47.2%) took \geq 3 doses of IPTp-SP (Fig.

162 2).

163

164 Fig 2. Proportion of uptake of ≥3 doses of IPTp-SP by number of ANC visits.

- 165
- 166

167 Socio-demographic characteristics of participants and uptake of

168 **≥3 doses of IPTp-SP**

169 There was no association between the stay in the place of residence and uptake of IPTp-170 SP (p = 0.844). A lower proportion of women with poor uptake of IPTp-SP had attended 171 secondary education compared to those who took more doses (39.6% vs. 52.1%, p < 0.001). 172 Furthermore, there were more illiterate among participants with poor uptake of IPTp-SP (40.9% 173 vs. 29.3%, p < 0.001). Only 1.8% (n = 99) of pregnant women were covered by some health 174 insurance; these were more represented among those who took ≥ 3 doses of IPTp-SP (p = 0.006). 175 A lower proportion of women with poor uptake of IPTp-SP had ever been in union with a 176 partner than women who received more doses (78.9% vs. 81.4%), though this association was 177 not statistically significant (p=0.054). Moreover, more women among those with poor uptake of IPTp-SP had a partner with a secondary or more level of education (68.8% vs. 61%, p < 178 179 0.001). The Sahelian regions were more represented among those who took less than 180 recommended 3 doses of IPTp-SP (39% vs. 32.8%) compare to those who took recommended 181 doses. The distribution of women across areas with varying levels of endemicity was 182 statistically different according to the uptake of IPTp-SP (p = 0.002).

183

Obstetrical history of participants and uptake of ≥ 3 doses of 184

IPTp-SP 185

Fewer women among those with poor uptake of IPTp-SP had a parity below 6 than among 186 187 those who took more doses (p = 0.033). Similarly, fewer women with poor uptake of IPTp-SP 188 had a history of terminated pregnancy (p = 0.022). There was a significant association between 189 highest ANC attendant and uptake of IPTp-SP (p < 0.001), with a greater proportion of women 190 among those with poor uptake of IPTp-SP having received no care (24% vs. 1.4%) and a lesser 191 proportion having been cared by a doctor (22.2 vs. 34.9). Only 41.1 % of pregnant women had 192 attended their first ANC visit before the fourth month of pregnancy; those were more 193 represented among women who took recommended doses of IPTp-SP (54.5% vs. 32.8%, p < 194 0.001). The majority of women (61.1%) had attended 4 to 7 ANC visits. The association between the number of ANC attended and the uptake of IPTp-SP was also significant (p < 195 196 0.001) and a greater proportion of the women who took recommended doses had attended over

197 4 visits (79.2% vs. 55.5%). (Table 2)

Variables		IPTp-SP uptake, n (%)		Rao-Scott $F(df1, df2)$	р
	Total N=5528	<3 doses n=3398	3+ doses n=2130		
Wanted pregnancy	4250 (76.9)	2585 (76.1)	1665 (78.2)	1.81 (1, 408)	0.180
Parity ≤ 5	4432 (80.2)	2682 (78.9)	1750 (82.1)	4,56 (1, 408)	0.033
History of terminated pregnancy	1023 (18.5)	584(17.2)	439 (20.6)	5.29 (1, 408)	0.022
ANC highest attendant					
No care	845 (15.3)	816 (24)	29 (1.4)	93.30 (2.75, 1123.61)	< 0.001
Doctor	1495 (27)	753 (22.2)	742 (34.9)		
Nurse/midwife	3012 (54.5)	1734 (51)	1278 (60)		
Others	176 (3.2)	95 (2.8)	80 (3.8)		
1 st ANC visit before/at 3 months	2274 (41.1)	1114 (32.8)	1160 (54.5)	172.05 (1, 408)	< 0.001
Number of ANC visits					
0	845 (15.3)	816 (24)	29 (1.4)	67.40 (4.61, 1880.81)	< 0.001
1	83 (1.5)	59 (1.7)	24 (1.1)		
2	233 (4.2)	167 (4.9)	66 (3.1)		

198
 Table 2. Obstetrical history and comparison between participants who took less than 3
 199 doses of IPTp-SP and others (N=5528)

3	793 (14.3)	469 (13.8)	324 (15.2)	
4 - 7	3379 (61.1)	1792 (52.7)	1586 (74.5)	
8 +	195 (3.5)	95 (2.8)	100 (4.7)	

200

IPTp-SP, Intermittent preventive treatment in pregnancy with Sulphadoxine pyrimethamine;

201 ANC, Antenatal care.

202

203 Determinants of the uptake of less than three doses of IPTp-SP

204 Table 3 shows the results of logistic regression analyses. It indicates that independent predictors 205 of poor uptake of IPTp-SP were age below 26 (p =0.038), residing in an area of lower 206 endemicity (p = 0.047), in the Sahelian regions (p < 0.001) and having attended less than 4 207 ANC visits (p = 0.006). Women residing in large cities (p = 0.001), who attended a first ANC 208 visit at 3 months or less of pregnancy (p < 0.001) and had been followed on ANC by a medical 209 doctor (p < 0.001), were less likely to receive less than 3 doses of IPTp-SP than those residing 210 in the southern regions, who attended first ANC visit latter and followed on by other health 211 care workers. Last, the effect of the cross-level interaction between the ANC highest attendant 212 and the Sahelian regions was positive and statistically significant (p < 0.001), indicating that 213 the effect of the ANC highest attendant on the risk of a woman receiving less than 214 recommended doses is conditional on whether the woman resides in the Sahelian regions; 215 notably, women attended by medical doctors in the Sahelian regions had an even lesser risk of 216 poor IPTp-SP uptake than those residing in the Southern regions (Fig 3).

IPTp-SP uptake, n (%) OR (95% CI) aOR (95% CI) Variables р <3 doses 3+ doses n=3398 n=2130 Age (years) 0-25 1323.74 (39.0) 1.16 (1.00-1.33) 1.17 (1.01-1.34) 755.34 (35.5) 0.038 2074.30 (61.0) 1374.76 (64.5) 26-49 1 Highest educational level 1.10 (0.90-1.32) No/ primary 2053.30 (60.4) 1019.06 (47.8) 1.66 (1.43-1.93) 0.378 Secondary, + 1344.71 (39.6) 1111.03 (52.2) 1

217 Determinants of the uptake of less than 3 doses of IPTp-SP by pregnant women

Christian					
Yes	2246.18 (66.1)	1539.66 (72.3)	0.74 (0.61-0.91)	1.00 (0.78-1.29)	0.971
No	1151.86 (33.9)	590.43 (27.7)	1		
Combined wealth index	, , , , , , , , , , , , , , , , , , ,				
Poor	1620.91 (47.7)	704.89 (33.1)	1.84 (1.54-2.20)	1.08 (0.87-1.33)	0.481
Middle to rich	1777.13 (52.3)	1425.21 (66.9)	1		
Covered by health	, , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , ,			
insurance					
Yes	44.88 (1.3)	53.802 (2.5)	0.51 (0.32-0.83)	0.76 (0.48-1.21)	0.252
No	3353.15 (98.7)	2076.29 (97.5)	1		
Ever in union					
Yes	2766.95 (81.4)	1680.74 (78.9)	1.17 (0.99-1.37)	1.06 (0.86-1.30)	0.570
No	631.09 (18.6)	449.36 (21.1)	1		
Partner's highest level of					
Yes	1061.65 (31.2)	830.97 (39.0)	1.41 (1.21-1.62)	0.91 (0.77-1.10)	0.330
No	2336.39 (68.8)	1299.12 (61.0)	1		
Region	, ,	,			
Sahelian regions	1326.32 (39.0)	698.56 (32.8)	2.12 (1.66-2.70)	5.72 (2.41-13.58)	<0.001
Douala/Yaounde	460.75 (13.6)	514.64 (24.2)	1.96 (1.57-2.45)	0.64 (0.50-0.84)	0.001
Southern regions	1610.96 (47.4)	916.89 (43.0)	1		
Type of Place of					
residence					
Rural	1999.90 (58.9)	910.65 (42.8)	1.91 (1.59-2.30)	1.22 (10.96-1.56)	0.108
Urban	1398.14 (41.1)	1219.44 (57.2)	1		
Malaria Prevalence (%)					
0-19	1620.75 (47.7)	1104.24 (51.8)	0.85 (0.70-1.02)	1.26 (1.00-1.58)	0.047
20 +	1777.29 (52.3)	1025.85 (48.2)	1		
Wanted pregnancy					
Yes	3244.12 (95.5)	2035.81 (95.6)	0.89 (0.74-1.05)	1.02 (0.72-1.46)	0.892
No	153.92 (4.5)	94.28 (4.4)	1		
Parity ≤ 5					
Yes	2681.88 (78.9)	1749.78 (82.1)	0.81 (0.67-0.98)	0.95 (0.76-1.19)	0.892
No	716.16 (21.1)	380.32 (17.9)	1		
Ever had a prematurely					
Yes	584 34 (17 2)	438 79 (20.6)	0.80 (0.66-0.96)	0 91 (0 74-1 11)	0.377
No	2813 70 (82.8)	1691 31 (79 4)	1		
ANC highest attendant					
Medical doctor	2576 04 (75 8)	2100 26 (98 6)	0.04 (0.03-0.06)	0 22 (0 13-0 36)	<0.001
Other	822 (24 2)	29.84 (1.4)	1	(0.12 (0.12 0.20)	
1 st ANC visit before/at 3					
months					
Yes	1114.99 (32.8)	1160.07 (54.5)	0.41 (0.35-0.46)	0.67 (0.57-0.78)	<0.001
No	2283.05 (67.2)	970.02 (45.5)	1		
Number of ANC visits					
< 4	1510.93 (44.5)	443.38 (20.8)	3.05 (2.53-3.66)	1.30 (1.08-1.57)	0.006

	\geq 4	1887.11 (55.5)	1686.71 (79.2)	1		
	ANC highest attendant: medical doctor by Sahelian regions*				-2.345 (0.468)	<0.001
218	IPTp-SP, Intermittent p	preventive treat	tment in pregna	ancy with Sulph	adoxine pyrimet	hamine;
219	ANC, Antenatal care.					
220	* Interaction effect (s.e)				
221						
222						
223	Fig 3. Cross-level inte	raction (ANC	highest attend	ant x Sahelian	regions region)	plot.
224						

225

226 **Discussion**

227 Since 2004 in Cameroon, IPTp-SP stands as a core strategy for the prevention of malaria in 228 pregnancy. We aimed to determine the proportion of, and identify the factors associated with 229 poor uptake of IPTp-SP. We found a high proportion (61.5%) of childbearing age women took 230 less than the recommended \geq 3 doses of IPTp-SP during their most recent pregnancy. Factors 231 associated comprised younger maternal age (aOR=1.17, CI: 1.01-1.35), residence in an area of 232 lower endemicity (aOR=1.26, CI: 1.00-1.58), residence in the Sahelian regions (aOR=5.81, CI: 233 2.46-13.69), and having attended less than 4 ANC visits (aOR=1.30, CI: 1.08-1.57); as well as 234 residence in large cities (aOR=0.65, CI: 0.50-0.84), having attended a first ANC visit at 3 235 months or less of pregnancy (aOR=0.66, CI: 0.57-0.78) and having been followed on ANC by 236 a medical doctor (aOR=0.22, CI: 0.13-0.35).

In line with the Rollback malaria (RBM) Partnership, Cameroon's ministry of health targets at 80% the 3 doses coverage of IPTp-SP by 2023 [15]. Though the found 38.5% are a big improvement from the 12.9% in 2011 [10]; the country still has some way to go. However, a

240 2013 cross-country DHS analytical study found the \geq 3 doses coverage of IPTp-SP varying 241 between 0.3% to 43% in sub-Saharan Africa, thus ranking Cameroon among the "high IPTp 242 coverage countries". Countries with reported lower \geq 3 doses coverage of IPTp-SP seem 243 characterized by greater malaria funding, unclear or tardily adopted relevant policy, lower 244 levels of ANC attendance with greater proportion of missed IPTp-SP administration 245 opportunities, and general healthcare system issues (as stock-outs or user fees) [16-19].

246 In Cameroon as in most sub-Saharan African countries, IPTp-SP distribution was mainly 247 channeled through the ANC program and has become an integral part of it. It ensues from this, 248 as we could find in our study, that women who have their 1st contact with health care providers 249 not early enough and who attend a lower number of subsequent visits are less likely to receive 250 the recommended doses. This concords with studies showing early timing of initial ANC visit 251 to improve uptake of IPTp-SP [17, 20-22]; and those demonstrating an increasing probability 252 of completing IPTp-SP doses with the number of attended ANC visits [10, 11, 23-25]. 253 Nonetheless, only 47.2% of women having attended over 4 visits did take recommended doses. 254 This depicts an important frequency of missed opportunities for IPTp-SP administration. 255 Barriers standing between ANC and uptake of ≥ 3 doses of IPTp-SP can be broadly grouped 256 into health system-related factors, ANC attendant related factors, maternal related factors. ANC 257 attendant qualification, as found here, can therefore determine the uptake of ≥ 3 doses of IPTp-258 SP, with doctors generally providing better care, when compared with other attendants. A study 259 in the northwest reported up to 35.9% of health providers had received no training on IPT and 260 about 30% not knowing when to start the preventive treatment [9], aligning with numerous 261 studies finding a poor general knowledge regarding intermittent preventive treatment among 262 healthcare providers [17].

263 Researchers equally report numerous maternal-related factors as predictors of poor IPTp3 264 uptake. We found younger age to be associated with poor uptake of \geq 3 doses of IPTp-SP. Age

is a rather unsettled factor across countries [17]. Our finding is however consistent with a study in the South-west region of Cameroon, though not statistically significant, supporting that younger women were seemingly showing lower interest for IPTp-SP [12]. A Nigerian study found similar results [21]. Younger women, with less maternal experience, might overlook the subtle symptoms of malaria in pregnancy, or underestimate its effects, thus the lower interest for the preventive treatment.

271 Our study furthermore shows that women residing in areas of higher endemicity had a higher 272 risk of not taking the three or more recommended doses of IPTp-SP. This supports the result of 273 the DHS multi-country analytical study showing an inverse association between the level of 274 malaria transmission and the uptake of \geq 3 doses of IPTp-SP [24]. A potential explanation would 275 be an increase in drug shortage or service overwhelming from the elevated demand or the 276 dodging of preventive doses because of recent treatment received for frequent infections. The 277 efficiency principle however calls for a better consideration of exposure when planning the 278 health initiative.

279 Also, women residing in the Sahelian regions of the country were found more likely to not 280 taking the recommended ≥ 3 doses of IPTp-SP compare to those residing in the southern 281 regions; and an opposite association was found for women residing in the great cities (Douala/ 282 Yaounde). The Sahelian regions contains 3 of the 5 regions where women report greater issues 283 with healthcare access [14]. The low level of socio-economic development in the region equally 284 renders healthcare delivery deficient, with the Far North, for example, only containing 8% of 285 Cameroonian doctors despite its 18% of the population [26]. These also give us a glimpse of 286 how the potential gain in women completing their doses of IPTp-SP from an added medical 287 doctor as ANC attendant would be significantly greater when added in the Sahelian regions 288 than in the southern regions; as our cross-level interaction term showed.

289

290

291 Conclusion

292 Despite significant improvement with time, coverage of ≥ 3 doses of IPTp-SP in Cameroon is 293 still low. We identified maternal age, malaria endemicity, place of residence, number of ANC 294 visits attended, timing of first ANC visit, and ANC attendant (which had its effect significantly 295 modified when residing in the Sahelian regions) as important predictors of the uptake of ≥ 3 296 doses of IPTp-SP. While pregnant women should be encouraged to strictly follow the ANC 297 policy recommendations, further studies should be carried to evaluate ANC attendant related 298 factors that could explain the elevated proportion of missed opportunities for IPTp-SP 299 administration. Furthermore, the finding of lower IPTp-SP uptake in area of higher endemicity 300 calls for better management of available resources. Greater attention shall be given to the 301 Sahelian regions, where policymakers shall first comprehend the specific obstacles to both 302 healthcare access and service delivery and develop strategies that overcome these obstacles.

303 Acknowledgments

We gratefully thank *The DHS Program* team, who has granting us access to the 2018 Cameroon
Demographic Health Survey database.

306

307 **References**

World Health Organization. World malaria report 2020: 20 years of global progress and
 challenges. Geneva: World Health Organisation; 2020. Available from:
 <u>https://apps.who.int/iris/rest/bitstreams/1321872/retrieve</u>. Accessed 27 Feb 2021.

Cottrell G, Moussiliou A, Luty AJF, Cot M, Fievet N, Massougbodji A, et al.
 Submicroscopic Plasmodium falciparum Infections Are Associated With Maternal Anemia,
 Premature Births, and Low Birth Weight. Clinical Infectious Diseases. 2015;60(10):1481-8.

314 3. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al.
315 Epidemiology and burden of malaria in pregnancy. The Lancet Infectious diseases.
316 2007;7(2):93-104.

Hartman TK, Rogerson SJ, Fischer PR. The impact of maternal malaria on newborns.
 Annals of tropical paediatrics. 2010;30(4):271-82.

319 5. Yimam Y, Nateghpour M, Mohebali M, Abbaszadeh Afshar MJ. A systematic review
320 and meta-analysis of asymptomatic malaria infection in pregnant women in Sub-Saharan
321 Africa: A challenge for malaria elimination efforts. PLOS ONE. 2021;16(4):e0248245.

World Health Organization. Global technical strategy for malaria 2016-2030. Geneva:
World Health Organisation; 2015. Available from:
https://apps.who.int/iris/handle/10665/176712. Accessed 27 Feb 2021.

Radeva-Petrova D, Kayentao K, ter Kuile FO, Sinclair D, Garner P. Drugs for
preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or
no treatment. The Cochrane database of systematic reviews. 2014;2014(10):Cd000169.

8. World Health Organization. Intermittent preventive treatment of malaria in pregnancy
using sulfadoxine-pyrimethamine (IPTp-SP): updated WHO policy recommendation. Geneva:

World Health Organization; 2012 2012. Contract No.: WHO/HTM/GMP.2012.05. Available
from: https://apps.who.int/iris/handle/10665/337990. Accessed 27 Feb 2021.

332 9. Diengou NH, Cumber SN, Nkfusai CN, Mbinyui MS, Zennobia VV, Bede F, et al.
333 Factors associated with the uptake of intermittent preventive treatment of malaria in pregnancy
334 in the Bamenda health districts, Cameroon. PAMJ. 2020;35(42).

10. Dionne-Odom J, Westfall AO, Apinjoh TO, Anchang-Kimbi J, Achidi EA, Tita ATN.

336 Predictors of the use of interventions to prevent malaria in pregnancy in Cameroon. Malaria337 Journal. 2017;16(1):132.

11. Leonard N, Eric FB, Judith AK, Samuel W. Factors associated to the use of insecticide

treated nets and intermittent preventive treatment for malaria control during pregnancy in

340 Cameroon. Archives of public health = Archives belges de sante publique. 2016;74:5.

Takem EN, Achidi EA, Ndumbe PM. Use of intermittent preventive treatment for
malaria by pregnant women in Buea, Cameroon. Acta tropica. 2009;112(1):54-8.

343 13. Republique du Cameroun. Enquête Démographique et de Santé du Cameroun 2004.
344 Yaoundé, Cameroun: Institut National de la Statistique (INS) Jun 2005.

14. Republique du Cameroun. Enquête Démographique et de Santé du Cameroun 2018.
Yaoundé, Cameroun: Institut National de la Statistique (INS) Fev 2020.

Republic of Cameroon. National Strategic Malaria Control Plan 2019-2023. Yaounde,
Cameroon: Ministry of public health Oct 2019. Available from: <u>https://pnlp.cm/plan-</u>
strategique/. Accessed 12 Mar 2021.

Andrews KG, Lynch M, Eckert E, Gutman J. Missed opportunities to deliver
intermittent preventive treatment for malaria to pregnant women 2003–2013: a systematic
analysis of 58 household surveys in sub-Saharan Africa. Malaria Journal. 2015;14(1):521.

353 Hill J, Hoyt J, van Eijk AM, D'Mello-Guyett L, Ter Kuile FO, Steketee R, et al. Factors 17. 354 affecting the delivery, access, and use of interventions to prevent malaria in pregnancy in sub-355 Saharan Africa: a systematic review and meta-analysis. PLoS Med. 2013;10(7):e1001488. Van Eijk AM, Hill J, Larsen DA, Webster J, Steketee RW, Eisele TP, et al. Coverage 356 18. of intermittent preventive treatment and insecticide-treated nets for the control of malaria 357 358 during pregnancy in sub-Saharan Africa: a synthesis and meta-analysis of national survey data, 359 2009-11. The Lancet Infectious diseases. 2013;13(12):1029-42. 360 19. World Health Organization. World malaria report 2016. Geneva: World Health 361 Organisation; 2016. Available from: https://apps.who.int/iris/rest/bitstreams/1321872/retrieve. 362 Accessed 27 Feb 2021. 363 Hill J, Dellicour S, Bruce J, Ouma P, Smedlev J, Otieno P, et al. Effectiveness of 20. 364 antenatal clinics to deliver intermittent preventive treatment and insecticide treated nets for the 365 control of malaria in pregnancy in Kenya. PloS one. 2013;8(6):e64913-e. 366 21. Iliyasu Z, Gajida AU, Galadanci HS, Abubakar IS, Baba AS, Jibo AM, et al. Adherence 367 to intermittent preventive treatment for malaria in pregnancy in urban Kano, northern Nigeria. 368 Pathog Glob Health. 2012;106(6):323-9. 369 22. Sangho O, Tounkara M, Whiting-Collins LJ, Beebe M, Winch PJ, Doumbia S. 370 Determinants of intermittent preventive treatment with sulfadoxine-pyrimethamine in pregnant women (IPTp-SP) in Mali, a household survey. Malaria Journal. 2021;20(1):231. 371 372 23. Azizi SC. Uptake of intermittent preventive treatment for malaria during pregnancy with Sulphadoxine-Pyrimethamine in Malawi after adoption of updated World Health 373 374 Organization policy: an analysis of demographic and health survey 2015–2016. BMC Public

375 Health. 2020;20(1):335.

376	24.	Florey L. Preventing Malaria during Pregnancy in Sub-Saharan Africa: Determinants
377	of Effe	ective IPTp Delivery. Calverton, Maryland, USA: ICF International; 2013 Sep. Available
378	from:]	https://dhsprogram.com/pubs/pdf/AS39/AS39.pdf. Accessed 27 Feb 2021.
379	25.	Olugbade OT, Ilesanmi OS, Gubio AB, Ajayi I, Nguku PM, Ajumobi O. Socio-
380	demog	raphic and regional disparities in utilization of intermittent preventive treatment for
381	malaria	a in pregnancy - Nigeria demographic health survey 2013. The Pan African medical
382	journal	l. 2019;32(Suppl 1):13.
383	26.	Bove APB, Robyn PJ, Singh R. Towards greater equity : a special focus on health.
384	Camer	oon economic update; issue no. 6. Washington, D.C.: World Bank Group Jan 2013.
385	Availa	ble from: http://documents.worldbank.org/curated/en/439211468224677542/Towards-

386 <u>greater-equity-a-special-focus-on-health</u>. Accessed 12 Jul 2021.

387



Final sample size; n = 5409 (unweighted) n = 5528 (weighted)

Figure



Figure



Figure